About palatin technologies inc - PTN
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.
PTN At a Glance
Palatin Technologies, Inc.
301 Carnegie Center Drive
Princeton, New Jersey 08540
| Phone | 1-609-495-2200 | Revenue | 13.19M | |
| Industry | Pharmaceuticals: Major | Net Income | -8,377,895.00 | |
| Sector | Health Technology | Employees | 25 | |
| Fiscal Year-end | 06 / 2027 | |||
| View SEC Filings |
PTN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.314 |
| Price to Book Ratio | 2.871 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.70 |
| Enterprise Value to Sales | 1.762 |
| Total Debt to Enterprise Value | 0.01 |
PTN Efficiency
| Revenue/Employee | 527,401.24 |
| Income Per Employee | -335,115.80 |
| Receivables Turnover | 43.838 |
| Total Asset Turnover | 2.236 |
PTN Liquidity
| Current Ratio | 4.608 |
| Quick Ratio | 4.608 |
| Cash Ratio | 4.228 |
PTN Profitability
| Gross Margin | 99.525 |
| Operating Margin | -65.743 |
| Pretax Margin | -63.541 |
| Net Margin | -63.541 |
| Return on Assets | -142.109 |
| Return on Equity | -877.533 |
| Return on Total Capital | -121.241 |
| Return on Invested Capital | -834.117 |
PTN Capital Structure
| Total Debt to Total Equity | 3.345 |
| Total Debt to Total Capital | 3.237 |
| Total Debt to Total Assets | 2.624 |
| Long-Term Debt to Equity | 0.978 |
| Long-Term Debt to Total Capital | 0.947 |